SAN DIEGO -- Assessment of chemicals in exhaled breath distinguished between benign and malignant pulmona . More than half of patients with non-small cell lung cancer and KRAS mutations had partial responses or stable disease when treated with the targeted agent sorafenib, a Dutch study showed.dry nodules with 80 to 90% accuracy, results of a small clinical study showed.
No comments:
Post a Comment